References
- American Cancer Society (ACS). Cancer Facts & Figures 2014. Atlanta, GA: ACS; 2014.
- Kennedy BJ, Fremgen AM, Menck HR. The National Cancer Data Base report on Hodgkin's disease for 1985–1989 and 1990–1994. Cancer 1998;83:1041–1047.
- Oza AM, Ganesan TS, Leahy M, et al. Patterns of survival in patients with Hodgkin's disease: Long follow up in a single centre. Ann Oncol 1993;4:385–392.
- Henry-Amar M, Somers R. Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease. Semin Oncol 1990;17:758–768.
- Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002;20:2101–2108.
- Chen AB, Punglia RS, Kuntz KM, et al. Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors. J Clin Oncol 2009;27:5383–5389.
- Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology 2009;1:497–506.
- Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011;117:4208–4217.
- Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group. Ann Oncol 2005;16:116–123.
- Surveillance, Epidemiology, and End Results Program [Internet]. SEER Stat Fact Sheets: Hodgkin Lymphoma. National Cancer Institute [cited 2014 May 30]. Available at: http://seer.cancer.gov/statfacts/html/hodg.html.
- Bradley CJ, Yabroff KR, Dahman B, et al. Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst 2008;100:1763–1770.
- Hansen RN, Ramsey SD, Slejko J, et al. The cost of relapse in Hodgkin lymphoma. J Clin Oncol 2014;32(suppl.)abstr e17537.
- Dryver ET, Jernström H, Tompkins K, et al. Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value. Br J Cancer 2003;89:482–486.
- Waters TM, Bennett CL, Pajeau TS, et al. Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know? Bone Marrow Transplant 1998;21:641–650.
- Freeman M, Vose J, Bennett C, et al. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995. Bone Marrow Transplant 1999;24: 679–684.
- Waters TM, Bennett CL, Vose JM. Economic analyses of new technologies: the case of stem-cell transplantation. J Clin Oncol 1997;15:2–4.
- Majhail NS, Mau LW, Denzen EM, et al. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. Bone Marrow Transplant 2013;48:294–300.